Log In
Print this Print this

Replagal, agalsidase alfa

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionInjectable alpha galactosidase A enzyme
Molecular Target Not available
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationFabry's disease
Indication DetailsTreat Fabry's disease
Regulatory Designation U.S. - Fast Track (Treat Fabry's disease);
U.S. - Priority Review (Treat Fabry's disease)
PartnerEndo International plc;
Sumitomo Dainippon Pharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today